期刊文献+
共找到25篇文章
< 1 2 >
每页显示 20 50 100
Interplay between micro RNA-17-5p, insulin-like growth factor-Ⅱ through binding protein-3 in hepatocellular carcinoma 被引量:3
1
作者 Danira Ashraf Habashy Hend Mohamed El Tayebi +3 位作者 Injie Omar Fawzy Karim Adel Hosny Gamal Esmat Ahmed Ihab Abdelaziz 《World Journal of Hepatology》 CAS 2016年第23期976-984,共9页
AIM: To investigate the effect of microR NA on insulinlike growth factor binding protein-3(IGFBP-3) and hence on insulin-like growth factor-Ⅱ(IGF-Ⅱ) bioavailability in hepatocellular carcinoma(HCC).METHODS: Bioinfor... AIM: To investigate the effect of microR NA on insulinlike growth factor binding protein-3(IGFBP-3) and hence on insulin-like growth factor-Ⅱ(IGF-Ⅱ) bioavailability in hepatocellular carcinoma(HCC).METHODS: Bioinformatic analysis was performed using microrna.org, DIANA lab and Segal lab softwares. Total RNA was extracted from 23 HCC and 10 healthy liver tissues using mir Vana mi RNA Isolation Kit. microR NA-17-5p(miR-17-5p) expression was mimicked and antagonized in Hu H-7 cell lines using Hi Per Fect Transfection Reagent, then total RNA was extracted using Biozol reagent then reverse transcribed into cD NA followed by quantification of mi R-17-5p and IGFBP-3 expression using Taq Man real-time quantitative PCR. Luciferase reporter assay was performed to validate the binding of miR-17-5p to the 3'UTR of IGFBP-3. Free IGF-Ⅱ protein was measured in transfected Hu H-7 cells using IGF-Ⅱ ELISA kit. RESULTS: Bioinformatic analysis revealed IGFBP-3 as a potential target for miR-17-5p. Screening of miR-17-5p and IGFBP-3 revealed a moderate negative correlation in HCC patients, where mi R-17-5p was extensively underexpressed in HCC tissues(P = 0.0012), while IGFBP-3 showed significant upregulation in the same set of patients(P = 0.0041) compared to healthy donors. Forcing mi R-17-5p expression in Hu H-7 cell lines showed a significant downregulation of IGFBP-3 mR NA expression(P = 0.0267) and a significant increase in free IGF-Ⅱ protein(P = 0.0339) compared to mock untransfected cells using unpaired t-test. Luciferase assay validated IGFBP-3 as a direct target of mi R-17-5p; luciferase activity was inhibited by 27.5% in cells co-transfected with miR-17-5p mimics and the construct harboring the wild-type binding region 2 of IGFBP-3 compared to cells transfected with this construct alone(P = 0.0474).CONCLUSION: These data suggest that regulating IGF-Ⅱ bioavailability and hence HCC progression can be achieved through targeting IGFBP-3 via manipulating the expression of miR NAs. 展开更多
关键词 insulin-like growth factor binding protein-3 insulin-like growth factor signaling pathway MicroR NA insulin-like growth factor-Ⅱ HEPATOCELLULAR carcinoma
下载PDF
Changes of insulin-like growth factor-Ⅱ and insulin-like growth factor binding protein-3 in cerebrospinal fluid of children with tuberculous meningitis
2
作者 Kai Sheng Guiling Fu +2 位作者 Yan Xing Ying Zhao Jinnan Yang 《Neural Regeneration Research》 SCIE CAS CSCD 2007年第8期483-486,共4页
BACKGROUND: Recent studies have found that insulin-like growth factors (IGFs) and insulin-like growth factor binding protein-3 (IGFBP-3) have stronger neurotrophic and neuroprotective effects. But whether their l... BACKGROUND: Recent studies have found that insulin-like growth factors (IGFs) and insulin-like growth factor binding protein-3 (IGFBP-3) have stronger neurotrophic and neuroprotective effects. But whether their levels in cerebrospinal fluid could be used as an auxiliary indicator in differentially diagnosing tuberculous meningitis and viral encephalitis is not yet clear. OBJECTIVE: To explore the changes of insulin-like growth factor-Ⅱ (IGF-Ⅱ ) and IGFBP-3 in cerebrospinal fluid (CSF) of children with tuberculous meningitis and the significance of the changes. DESIGN: A non-randomized concurrent controlled study. SETTING: Department of Pediatric Internal Medicine, the First Affiliated Hospital of Xinxiang Medical College. PARTICIPANTS: Thirty children with tuberculous meningitis (14 males and 16 females) were selected from the Department of Pediatric Internal Medicine, the First Affiliated Hospital of Xinxiang Medical College from January 2005 to December 2006. Tuberculous meningitis was diagnosed according to their clinical manifestations, the history of close contact with tuberculosis, typical cerebrospinal fluid changes of tuberculous meningitis, positive tuberculosis antibody and effective antituberculosis treatment. There were 30 children (13 males and 17 females) with viral encephalitis, and viral encephalitis was diagnosed according to epidemiological history, clinical manifestations, conventional and biochemical changes of cerebrospinal fluid, and negative bacteriology judgment. Meanwhile, 30 children (13 males and 17 females) without infectious and central nervous system disease were selected as the control group. Informed consent was obtained from the parents of all the enrolled children. METHODS: ①The lumbar puncture operation was implemented immediately to obtain cerebrospinal fluid (3 mL). The contents of IGF-Ⅱ and IGFBP-3 were detected with immunoradiometric assay. The concentrations of glucose and protein in cerebrospinal fluid were determined with a dry-chemical method. The number of white blood cells was counted by Fushi Method. ②The Pearson correlation analysis was used to analyze the correlation of the contents of IGF-Ⅱ and IGFBP-3 in cerebrospinal fluid with the leucocyte counting and the concentrations of glucose and protein in cerebrospinal fluid. MAIN OUTCOME MEASURES: The contents of IGF- Ⅱ and IGFBP-3 in cerebrospinal fluid, and their correlation with the leucocyte counting and the concentrations of glucose and protein in cerebrospinal fluid. RESULTS: ①Contents of IGF-Ⅱ and IGFBP-3 in cerebrospinal fluid: The contents of IGF-Ⅱ and IGFBP-3 in cerebrospinal fluid in the tuberculous meningitis group were significantly higher than those in the encephalitis virus group and control group (P 〈 0.05). There was no significant difference in the contents of IGF- Ⅱ and IGFBP-3 in cerebrospinal fluid between the viral encephalitis group and control group (P 〉 0.05). ②Correlation: The IGF- Ⅱ and IGFBP-3 contents in cerebrospinal fluid were positively correlated with the protein concentration in cerebrospinal fluid (r =0.821, 0.855, P 〈 0.01), but negatively with the glucose (r =0.742, - 0.605, P 〈 0.01). CONCLUSION- ①IGFs and IGVBPs are involved in the pathophysiological process of tuberculous meningitis, as well as the glucose and protein metabolism in cerebrospinal fluid. ②The IGF-Ⅱ and IGFBP-3 contents in cerebrospinal fluid can be used as the auxiliary indicators to differentially diagnose tuberculous meningitis and viral enceohalitis. 展开更多
关键词 tuberculous meningitis insulin-like growth factor-Ⅱ insulin-like growth factor binding protein-3
下载PDF
Effects of Exogenous Growth Hormone on Growth Hormone-Insulin-Like Growth Factor Axis of Human Gastric Cancer Cell 被引量:1
3
作者 Daoming Liang Yi Zhang +3 位作者 Jiayong Chen Hua Wang Tao Huang Xin Xue 《Chinese Medicine》 2014年第4期259-269,共11页
Aim: To study effects of recombinant human growth hormone (rhGH) on growth hormone-insulin-like growth factor axis (GH-IGFs) of human gastric cancer cell in vivo in order to reveal part mechanism of growth effects of ... Aim: To study effects of recombinant human growth hormone (rhGH) on growth hormone-insulin-like growth factor axis (GH-IGFs) of human gastric cancer cell in vivo in order to reveal part mechanism of growth effects of rhGH on gastric cancer. Methods: Nude mice were randomly divided into control group, cisplatin (DDP) group, rhGH group and DDP + rhGH group after human gastric cancer xenograft model of node mice was successfully founded and drugs were used for 6 days. We investigated volume of tumor, inhibitory rate of tumor and cell cycle by slide gauge and flow cytometry. In addition, We also respectively investigated insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) of blood serum of nude mice, IGF-ImRNA, insulin-like growth factor-I receptor (IGF-IR) mRNA and IGFBP-3 mRNA of xenograft of nude mice by enzyme linked immunosorbent assay (ELISA) and semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) on the first day of completing use of drugs later. Results: Tumor grew obviously slowly and tumor inhibitory rate obviously rose in DDP group and DDP + rhGH group compared with control group and rhGH group (p p p < 0.05). Expressions of IGF-I mRNA and IGF-IR mRNA were not obviously different in all groups. But expression of IGFBP-3 mRNA obviously increased in rhGH group, DDP group and DDP + rhGH group compared with control group;meanwhile, expression of IGFBP-3 mRNA also obviously increased in DDP + rhGH group compared with control group, DDP group and rhGH group. Conclusion: Our results indicated rhGH in short-time use did not improve proliferation of human gastric cancer cells and its mechanism was possible that rhGH in short-time use raised simultaneously IGF-I and IGFBP-3 of blood serum and increased IGFBP-3 mRNA, but degraded ratio of IGF-I and IGFBP-3 of blood serum in human gastric cancer cells. 展开更多
关键词 human growth Hormone Stomach NEOPLASM insulin-like growth factor insulin-like growth factor binding protein-3 RT-Polymerase Chain Reaction
下载PDF
IGF-1/IGFBP-3、Klotho联合p21 waf/cip1对特发性矮小症儿童rhGH干预后年生长速率的预测效能
4
作者 陈云秋 刘静 杨红 《海南医学》 CAS 2024年第24期3548-3553,共6页
目的探讨胰岛素生长因子-1(IGF-1)/胰岛素样生长因子结合蛋白-3(IGFBP-3)、抗衰老物质Klotho联合细胞周期调节物质p21 waf/cip1对特发性矮小症(ISS)儿童注射用重组人生长激素(rhGH)干预后年生长速率(GV)的预测效能。方法选取2021年4月至... 目的探讨胰岛素生长因子-1(IGF-1)/胰岛素样生长因子结合蛋白-3(IGFBP-3)、抗衰老物质Klotho联合细胞周期调节物质p21 waf/cip1对特发性矮小症(ISS)儿童注射用重组人生长激素(rhGH)干预后年生长速率(GV)的预测效能。方法选取2021年4月至2023年6月南阳市中心医院收治的150例ISS患者进行前瞻性研究,根据rhGH干预后GV分为低(GV<5 cm/年,25例)、中(GV介于5~7 cm/年,34例)、高(GV>7 cm/年,91例)GV组。比较三组患儿治疗前的IGF-1/IGFBP-3、Klotho、p21 waf/cip1水平,采用Pearson相关性分析治疗前IGF-1/IGFBP-3、Klotho、p21 waf/cip1水平与rhGH干预后GV的相关性,消除了其他可能因素的影响后,采用净相关性分析治疗前IGF-1/IGFBP-3、Klotho、p21 waf/cip1水平与rhGH干预后GV的相关性,采用受试者工作特征(ROC)曲线评估治疗前IGF-1/IGFBP-3、Klotho、p21 waf/cip1及其联合检测对rhGH干预后GV的预测效能。结果治疗前,高GV组患儿的IGF-1/IGFBP-3、Klotho、rhGH干预后GV分别为0.18±0.05、(1672.20±356.38)pg/mL、(8.79±0.58)cm/年,明显高于低GV组[0.07±0.02、(905.65±281.13)pg/mL、(4.22±0.24)cm/年]和中GV组[0.12±0.04、(1294.33±327.52)pg/mL、(6.15±0.26)cm/年],且中GV组明显高于低GV组,差异均有统计学意义(P<0.05);治疗前,高GV组患儿的p21 waf/cip1为(0.16±0.05)pg/mL,明显低于中GV组的(0.23±0.07)pg/mL和低GV组的(0.39±0.13)pg/mL,且中GV组明显低于低GV组,差异均有统计学意义(P<0.05);Pearson相关性分析结果显示,治疗前IGF-1/IGFBP-3、Klotho与rhGH干预后GV呈正相关(P<0.05),p21 waf/cip1与rhGH干预后GV呈负相关(P<0.05);净相关性分析结果显示,治疗前IGF-1/IGFBP-3、Klotho、p21 waf/cip1水平仍与rhGH干预后GV显著相关(P<0.05);ROC分析结果显示,三者及联合预测rhGH干预后获得中GV的AUC分别为0.799、0.766、0.768、0.931,其中联合的AUC最大;三者及联合预测rhGH干预后获得高GV的AUC分别为0.809、0.740、0.828、0.943,其中联合的AUC亦最大。结论治疗前IGF-1/IGFBP-3、Klotho、p21 waf/cip1与ISS儿童rhGH干预后GV显著相关,可作为预测rhGH敏感性的标志物,联合检测时能进一步提高预测性能,为临床早期预测rhGH的敏感性提供重要的参考信息。 展开更多
关键词 特发性矮小症 胰岛素生长因子-1/胰岛素样生长因子结合蛋白-3 抗衰老物质 细胞周期调节物质 注射用重组人生长激素 年生长速率 预测效能
下载PDF
IGFBP-3 promotes cachexia-associated lipid loss by suppressing insulin-like growth factor/insulin signaling 被引量:3
5
作者 Xiaohui Wang Jia Li +8 位作者 Wei Zhang Feng Wang Yunzi Wu Yulin Guo Dong Wang Xinfeng Yu Ang Li Fei Li Yibin Xie 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第8期974-985,共12页
Background:Progressive lipid loss of adipose tissue is a major feature of cancer-associated cachexia.In addition to systemic immune/inflammatory effects in response to tumor progression,tumor-secreted cachectic ligand... Background:Progressive lipid loss of adipose tissue is a major feature of cancer-associated cachexia.In addition to systemic immune/inflammatory effects in response to tumor progression,tumor-secreted cachectic ligands also play essential roles in tumor-induced lipid loss.However,the mechanisms of tumor-adipose tissue interaction in lipid homeostasis are not fully understood.Methods:The yki-gut tumors were induced in fruit flies.Lipid metabolic assays were performed to investigate the lipolysis level of different types of insulin-like growth factor binding protein-3(IGFBP-3)treated cells.Immunoblotting was used to display phenotypes of tumor cells and adipocytes.Quantitative polymerase chain reaction(qPCR)analysis was carried out to examine the gene expression levels such as Acc1,Acly,and Fasn et al.Results:In this study,it was revealed that tumor-derived IGFBP-3 was an important ligand directly causing lipid loss in matured adipocytes.IGFBP-3,which is highly expressed in cachectic tumor cells,antagonized insulin/IGF-like signaling(IIS)and impaired the balance between lipolysis and lipogenesis in 3T3-L1 adipocytes.Conditioned medium from cachectic tumor cells,such as Capan-1 and C26 cells,contained excessive IGFBP-3 that potently induced lipolysis in adipocytes.Notably,neutralization of IGFBP-3 by neutralizing antibody in the conditioned medium of cachectic tumor cells significantly alleviated the lipolytic effect and restored lipid storage in adipocytes.Furthermore,cachectic tumor cells were resistant to IGFBP-3 inhibition of IIS,ensuring their escape from IGFBP-3-associated growth suppression.Finally,cachectic tumor-derived ImpL2,the IGFBP-3 homolog,also impaired lipid homeostasis of host cells in an established cancer-cachexia model in Drosophila.Most importantly,IGFBP-3 was highly expressed in cancer tissues in pancreatic and colorectal cancer patients,especially higher in the sera of cachectic cancer patients than non-cachexia cancer patients.Conclusion:Our study demonstrates that tumor-derived IGFBP-3 plays a critical role in cachexia-associated lipid loss and could be a biomarker for diagnosis of cachexia in cancer patients. 展开更多
关键词 BIOMARKER Cancer CACHEXIA insulin-like growth factor binding protein-3 Lipid loss
原文传递
血清胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3在矮小症儿童诊断和疗效判断中的价值 被引量:23
6
作者 谢理玲 柯江维 +5 位作者 杨玉 杨利 李玲芳 周斌 吴限 邹海英 《实用儿科临床杂志》 CAS CSCD 北大核心 2008年第20期1604-1606,共3页
目的探讨胰岛素样生长因子-1(IGF-1)及其结合蛋白-3(IGFBP-3)在矮小症儿童诊断及疗效判断中的价值。方法1.对124例青春发育前矮小症患儿用精氨酸激发试验和可乐定激发试验检测其血清生长激素(GH)水平,并根据患儿GH峰值分为生长激素缺乏... 目的探讨胰岛素样生长因子-1(IGF-1)及其结合蛋白-3(IGFBP-3)在矮小症儿童诊断及疗效判断中的价值。方法1.对124例青春发育前矮小症患儿用精氨酸激发试验和可乐定激发试验检测其血清生长激素(GH)水平,并根据患儿GH峰值分为生长激素缺乏组(GHD组,40例)、特发性矮小组(ISS组,84例)。选取20例健康儿童作为健康对照组。对所有儿童采用酶联免疫吸附法检测血清IGF-1和IGFBP-3。对GHD组、ISS组和健康对照组儿童血清IGF-1和IGFBP-3水平进行两两比较。2.对15例GHD和30例ISS患儿予国产重组人生长激素(rhGH)0.1 IU/(kg.d)治疗6个月,于治疗前及治疗6个月分别测定其身高、体质量、骨龄及血清IGF-1、IGFBP-3,并进行治疗前后的对照。结果1.GHD组和ISS组患儿血清IGF-1和IGFBP-3水平明显低于健康对照组(Pa<0.01),GHD组与ISS组患儿血清IGF-1和IGFBP-3水平比较均有显著差异(Pa<0.01),GHD组患儿治疗前后血清IGF-1、IGFBP-3比较有显著差异(Pa<0.01);诊断GHD,IGF-1的特异性为67.8%,敏感性为75%;IGFBP-3的特异性为88%,敏感性为85%。2.rhGH治疗后身高增长速度明显加快,血清IGF-1、IGFBP-3水平显著升高;治疗前血清IGF-1与治疗6个月生长速度呈显著负相关(r=-0.78 P<0.01);治疗6个月后IGF-1的变化与治疗后生长速度呈显著正相关(r=0.82 P<0.01)。结论IGF-1、IGFBP-3可用于儿童矮小症的诊断及疗效评价。 展开更多
关键词 矮小症 胰岛素样生长因子-1 胰岛素样生长因子结合蛋白-3 重组人生长激素 儿童
下载PDF
IGF-1、IGFBP-3在儿童生长激素缺乏症诊断和疗效判断中的应用 被引量:5
7
作者 李堂 张颖 +2 位作者 陈志红 董增义 罗小平 《山东医药》 CAS 北大核心 2006年第23期15-17,共3页
目的探讨胰岛素样生长因子1(IGF-1)及其结合蛋白3(IGFBP-3)在儿童生长激素缺乏症(GHD)诊断及疗效判断中的价值。方法68例GHD患儿予以国产0.1 IU/(kg.d)r-hGH治疗12个月,于治疗前及治疗后3、6、12个月分别测定身高、体重、骨龄及血清IGF-... 目的探讨胰岛素样生长因子1(IGF-1)及其结合蛋白3(IGFBP-3)在儿童生长激素缺乏症(GHD)诊断及疗效判断中的价值。方法68例GHD患儿予以国产0.1 IU/(kg.d)r-hGH治疗12个月,于治疗前及治疗后3、6、12个月分别测定身高、体重、骨龄及血清IGF-1、IGFBP-3,并与60例正常儿童进行对照。结果GHD患儿血清IGF-1和IGFBP-3水平明显低于正常对照组(P均<0.01);r-hGH治疗后身高增长速度明显加快,血清IGF-1、IGFBP-3水平显著升高;治疗前血清IGF-1与治疗6、12个月时的生长速度(GV6,GV12)呈负相关(r=-0.72-、0.78,P均<0.01);治疗3个月时IGFBP-3水平变化与GV6、GV12呈正相关(r=0.82、0.80,P均<0.01)。结论IGF-1、IGFBP-3可用于儿童GHD的诊断及疗效预测。 展开更多
关键词 生长激素缺乏症 胰岛素样生长因子1 胰岛素样生长因子结合蛋白3 重组人生长激素 儿童
下载PDF
生长激素治疗儿童特发性矮身材的促生长疗效与血清IGF-1、IGFBP-3关系研究 被引量:10
8
作者 侯小霞 娄丹 乔召华 《中国实用医药》 2015年第23期1-3,共3页
目的分析基因重组人生长激素(r-h GH)治疗特发性矮身材(ISS)儿童的促生长疗效与血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的关系。方法 50例ISS儿童给予国产r-h GH治疗12个月。治疗前、治疗后的每3个月分别... 目的分析基因重组人生长激素(r-h GH)治疗特发性矮身材(ISS)儿童的促生长疗效与血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的关系。方法 50例ISS儿童给予国产r-h GH治疗12个月。治疗前、治疗后的每3个月分别测定身高、体重、血糖、甲状腺功能、IGF-1及IGFBP-3等,并在治疗前、治疗后的6个月及12个月测定骨龄。结果治疗后的身高、生长速率(GV)均较治疗前增高(P<0.05);骨龄与年龄之比(BA/CA)在治疗后6、12个月与治疗前相比,差异无统计学意义(P>0.05);治疗后每3个月的IGF-1、IGFBP-3均较治疗前增加,差异有统计学意义(P<0.05);治疗前IGF-1、IGFBP-3与治疗后每3个月的GV增加量均呈负相关(P<0.05)。治疗后每3个月IGF-1、IGFBP-3增加量与同期GV增加量均呈正相关(P<0.05)。结论 r-h GH治疗ISS儿童总体安全有效,IGF-1及IGFBP-3对预测r-h GH治疗ISS的疗效有一定的价值。 展开更多
关键词 基因重组人生长激素 特发性矮身材 胰岛素样生长因子-1 胰岛素样生长因子结合蛋白-3
下载PDF
不同剂量重组人生长激素治疗对特发性矮小症患儿身高、体重以及血清IGF-1和IGFBP-3表达的影响 被引量:74
9
作者 郭艳艳 蒋成霞 +1 位作者 姚兰 黄炜 《解放军医药杂志》 CAS 2020年第3期44-47,共4页
目的分析不同剂量重组人生长激素(r-hGH)治疗对特发性矮小症(ISS)患儿身高、体重以及血清胰岛素样生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)表达的影响。方法回顾性分析2014年3月—2018年4月收治的58例ISS患儿的临床资... 目的分析不同剂量重组人生长激素(r-hGH)治疗对特发性矮小症(ISS)患儿身高、体重以及血清胰岛素样生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)表达的影响。方法回顾性分析2014年3月—2018年4月收治的58例ISS患儿的临床资料。按照r-hGH应用剂量不同分为大剂量组31例[r-hGH 0.2 U/(kg·d)皮下注射]和小剂量组27例[r-hGH 0.1 U/(kg·d)皮下注射]。比较2组治疗前和治疗12个月后生长情况相关指标:身高、体重、生长速度(GV)、身高标准差积分(Ht SDS)水平差异,比较血清IGF-1、IGFBP-3以及骨代谢相关指标:Ⅰ型前胶原氨基端前肽(PⅠNP)、骨碱性磷酸酶(BAP)、Ⅰ型胶原交联羧基末端肽(β-CTX)水平差异,观察不良反应发生情况。结果治疗后,2组身高、体重、GV、Ht SDS以及血清IGF-1、IGFBP-3、PⅠNP、BAP水平均较治疗前明显升高,且大剂量组明显高于小剂量组(P<0.05)。治疗后,2组血清β-CTX水平均较治疗前明显降低,且大剂量组明显低于小剂量组(P<0.05)。2组总不良反应发生率比较差异无统计学意义(P>0.05)。结论大剂量r-hGH更有利于促进ISS患儿生长,改善患儿血清IGF-1、IGFBP-3水平和骨代谢,且安全性良好。 展开更多
关键词 特发性矮小症 重组人生长激素 身高 胰岛素样生长因子-1 胰岛素样生长因子结合蛋白-3 碱性磷酸酶
下载PDF
重组人生长激素对特发性矮小患儿症血清胰岛素样生长因子1与胰岛素样生长因子结合蛋白3水平的影响 被引量:20
10
作者 干冬梅 石小军 《中国生化药物杂志》 CAS 2015年第12期51-53,共3页
目的探讨重组人生长激素对特发性矮小症患儿血清胰岛素样生长因子1(insulin-like growth factor-1,IGF-1)与胰岛素样生长因子结合蛋白3(insulin-like growth factor binding protein-3,IGFBP-3)水平的影响。方法收集宁波市妇女儿童医院... 目的探讨重组人生长激素对特发性矮小症患儿血清胰岛素样生长因子1(insulin-like growth factor-1,IGF-1)与胰岛素样生长因子结合蛋白3(insulin-like growth factor binding protein-3,IGFBP-3)水平的影响。方法收集宁波市妇女儿童医院儿5科收治的特发性矮小症患儿48例,随机分为对照组和实验组,每组各24例,对照组患儿给予营养治疗,实验组在对照组基础上给予重组人生长激素治疗,均治疗12个月。治疗结束后,对所有患儿的血清胰岛素样生长因子1、胰岛素样生长因子结合蛋白3水平及身高进行检测。结果与对照组治疗后比较,实验组患儿的血清IGF-1水平较高(P<0.05);实验组患儿的血清IGFBP-3水平较高(P<0.05);实验组患儿的身高较高(P<0.05)。结论重组人生长激素能够显著提高特发性矮小症患儿血清IGF-1、IGFBP-3水平,促进患儿生长,对临床有指导意义。 展开更多
关键词 重组人生长激素 特发性矮小症 胰岛素样生长因子1 胰岛素样生长因子结合蛋白3
下载PDF
Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis 被引量:7
11
作者 Shi-Min Luo Wei-Min Tan +2 位作者 Wei-Xiong Deng Si-Min Zhuang Jian-Wei Luo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第27期4272-4276,共5页
AIM: To explore the expression of albumin (ALB), insulinlike growth factor (IGF)-I, and insulin-like growth factor binding protein (IGFBP)-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular car... AIM: To explore the expression of albumin (ALB), insulinlike growth factor (IGF)-I, and insulin-like growth factor binding protein (IGFBP)-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma (HCC) patients with cirrhosis.METHODS: Twenty-four HCC patients with cirrhosis who underwent hepatectomy were studied. ALB mRNA, IGF-1 mRNA, and IGFBP-3 mRNA in liver tissues (including tumor tissues and adjacent non-tumor tissues) were detected by reverse transcriptase-polymerase chain reaction(RT-PCR). Liver Ki67 immunohistochemistry staining was studied. At the same time, 12 patients with cholelithiasis or liver angioma who underwent operation were segregated as normal control.RESULTS: In HCC patients with cirrhosis, hepatic ALB mRNA, IGF-1 mRNA, and IGFBP-3 mRNA of tumor tissues or adjacent non-tumor tissues were lower than the normal liver tissues, while in tumor tissues, hepatic ALB mRNA and IGFBP-3 mRNA were lower, hepatic IGF-1 mRNA was higher than in adjacent non-tumor tissues. Liver Ki67 labeling index (Ki67 LI) in tumor tissues or adjacent nontumor tissues were higher than that in the normal liver tissues, while in tumor tissues it was higher than that in adjacent non-tumor tissues.CONCLUSION: Imbalance of IGF-1 and IGFBP-3 may play a role in hepatocarcinogenesis and tumor development of liver cirrhosis patients. 展开更多
关键词 Hepatocellular carcinoma Insulin growth factor-i insulin-like growth factor binding protein-3
下载PDF
重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清LMTK-3、IGFBP-7的影响 被引量:13
12
作者 韩敏 王坚 王久胜 《中国现代医学杂志》 CAS 2018年第9期55-59,共5页
目的探讨重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清Lemur酪氨酸激酶3(LMTK-3)、胰岛素样生长因子结合蛋白7(IGFBP-7)的影响。方法选取2012年1月-2015年1月于该院收治的NSCLC患者86例为研究对象,按随机数字表法分为观察组和对照... 目的探讨重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清Lemur酪氨酸激酶3(LMTK-3)、胰岛素样生长因子结合蛋白7(IGFBP-7)的影响。方法选取2012年1月-2015年1月于该院收治的NSCLC患者86例为研究对象,按随机数字表法分为观察组和对照组,每组43例。对照组患者采取吉西他滨+顺铂化疗。观察组在对照组基础上联合恩度治疗。对两组患者的临床疗效、不良反应、外周血血管内皮生长因子(VEGF)、胰岛素样生长因子1(IGF-1)、LMTK-3、IGFBP表达水平进行评价。结果观察组治疗客观有效率、总有效率高于对照组(P<0.05),观察组的疗效优于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应发生率并差异无统计学意义(P>0.05)。两组患者治疗后VEGF、IGF-1及LMTK-3水平较治疗前更低,GFBP水平较治疗后更高,差异有统计学意义(P<0.05),且观察组治疗后VEGF、IGF-1及LMTK-3水平较对照组更低,IGFBP-7更高,差异有统计学意义(P<0.05)。结论重组人内皮抑素联合化疗可有效降低NSCLC患者的血清LMTK3水平,升高血清IGFBO-7水平,患者的疗效良好,不良反应较低。 展开更多
关键词 重组人内皮抑素 化疗 晚期非小细胞肺癌 Lemur酪氨酸激酶3 胰岛素样生长因子结合蛋白-7
下载PDF
rhIGF-1/BP3对新生幼鼠支气管肺发育不良的预防作用
13
作者 陈爽 陈信 +1 位作者 瞿色华 董淮富 《贵州医科大学学报》 CAS 2023年第8期925-930,共6页
目的探讨重组人胰岛素样生长因子结合蛋白-3(rhIGF-1/BP3)对新生幼鼠支气管肺发育不良(BPD)的预防作用。方法35只SPF级怀孕Wistar大鼠,10只喂养22 d后剖宫产娩出幼鼠作为对照组(腹腔注射生理盐水1 mg/kg),其余25只大鼠建模成功获得20只... 目的探讨重组人胰岛素样生长因子结合蛋白-3(rhIGF-1/BP3)对新生幼鼠支气管肺发育不良(BPD)的预防作用。方法35只SPF级怀孕Wistar大鼠,10只喂养22 d后剖宫产娩出幼鼠作为对照组(腹腔注射生理盐水1 mg/kg),其余25只大鼠建模成功获得20只BPD模型幼鼠均分为BPD模型组(腹腔注射生理盐水1 mg/kg)及干预组(给予rhIGF-1/BP31 mg/kg);比较干预2周后3组新生幼鼠的体质量及生存率,比较干预前后3组新生幼鼠的肺功能[呼气阻力(Re)、吸气阻力(Ri)、最大通气量(MVV)、肺顺应性(C1)、第0.3秒用力呼气容积占用力肺活量的比值(FEV0.3/FVC)]和肺动脉平均压、心输出量、右心室壁厚度、右心室腔大小,比较干预2周后3组新生幼鼠的肺泡计数水平、肺泡平均截距及肺组织胰岛素样生长因子-1(IGF-1)蛋白相对表达量。结果干预后,模型组新生幼鼠体质量、生存率、MVV、C1、FEV0.3/FVC、心输出量、肺泡计数水平、IGF-1蛋白相对表达量较对照组降低,Re、Ri、肺动脉平均压、右心室壁厚度、右心室腔大小、肺泡平均截距水平较对照组升高(P<0.05);干预组新生幼鼠体质量、生存率、MVV、C1、FEV0.3/FVC、心输出量、肺泡计数水平、IGF-1蛋白相对表达量较模型组升高,Re、Ri、肺动脉平均压、右心室壁厚度、右心室腔大小、肺泡平均截距水平较模型组降低(P<0.05)。结论腹腔注射rhIGF-1/BP3干预后,BPD新生幼鼠生长情况、肺功能、心功能均得到改善,肺功脉平均压降低,其机制可能与IGF-1表达量有关。 展开更多
关键词 支气管肺发育不良 肺动脉高压 重组人胰岛素样生长因子结合蛋白-3 肺功能 胰岛素样生长因子-1 心功能
下载PDF
重组人生长激素对特发性矮小症儿童血清IGF-1/IGFBP-3摩尔比的影响及其临床意义 被引量:5
14
作者 张静静 贾媛媛 +1 位作者 胡苗苗 成胜权 《东南大学学报(医学版)》 CAS 2023年第5期681-687,共7页
目的:探讨重组人生长激素(rhGH)对特发性矮小症(ISS)儿童血清胰岛素样生长因子-1(IGF-1)/IGF结合蛋白-3(IGFBP-3)摩尔比的影响及临床意义。方法:收集我院2016年6月至2020年6月收治的132例学龄期ISS儿童的临床和实验室记录进行回顾性分析... 目的:探讨重组人生长激素(rhGH)对特发性矮小症(ISS)儿童血清胰岛素样生长因子-1(IGF-1)/IGF结合蛋白-3(IGFBP-3)摩尔比的影响及临床意义。方法:收集我院2016年6月至2020年6月收治的132例学龄期ISS儿童的临床和实验室记录进行回顾性分析,所有儿童接受至少2年的rhGH治疗。采用化学发光法测定血清IGF-1和IGFBP-3浓度,并计算摩尔比。rhGH治疗前后数据差值(Δ)=治疗后值-治疗前值。rhGH治疗1年后Δ身高标准差分值(SDS)<0.3定义为治疗反应不良,Δ身高SDS≥0.3定义为治疗反应良好。结果:与基线相比,rhGH治疗1年和2年身高SDS、IGF-1 SDS、IGFBP-3 SDS以及IGF-1/IGFBP-3摩尔比SDS均增加(P<0.05)。rhGH治疗反应不良的学龄期ISS儿童基线时的实际年龄、骨龄明显高于反应良好儿童,同时IGF-1/IGFBP-3摩尔比和IGF-1/IGFBP-3摩尔比SDS明显低于反应良好儿童(P<0.05)。经多因素Logistic回归分析,基线时IGF-1/IGFBP-3摩尔比SDS较低是rhGH治疗反应不良的独立危险因素(P<0.001)。rhGH治疗1年或2年后的Δ身高SDS与ΔIGF-1/IGFBP-3摩尔比、ΔIGF-1/IGFBP-3摩尔比SDS呈正相关(P<0.05)。进一步校正作为协变量的基线身高后,治疗2年后Δ身高SDS与ΔIGF-1/IGFBP-3摩尔比SDS呈正相关(P<0.05)。结论:血清IGF-1/IGFBP-3摩尔比SDS与rhGH治疗后身高增加反应相关,可能适合作为预测学龄期ISS儿童接受rhGH治疗后身高反应的生物标志物。 展开更多
关键词 重组人生长激素 特发性矮小症 胰岛素样生长因子-1/胰岛素样生长因子结合蛋白-3摩尔比 身高标准差分值
下载PDF
特发性矮小症儿童rhGH治疗第八天血清中IGF-1和IGFBP-3变化与疗效关系的研究 被引量:10
15
作者 杨立础 谢志明 +3 位作者 张宇 李温慈 郑靖阳 林峰 《海峡药学》 2014年第7期172-175,共4页
目的探讨重组人生长激素(rhGH)治疗特发性矮小症(ISS)第八天,血清中类胰岛素样生长因子-1(IGF-1)和类胰岛素样生长因子结合蛋白(IGFBP-3)浓度变化与疗效的关系。方法 60例特发性矮小症儿童,用rhGH治疗,剂量为0.15IU/(kg·d),疗程6个... 目的探讨重组人生长激素(rhGH)治疗特发性矮小症(ISS)第八天,血清中类胰岛素样生长因子-1(IGF-1)和类胰岛素样生长因子结合蛋白(IGFBP-3)浓度变化与疗效的关系。方法 60例特发性矮小症儿童,用rhGH治疗,剂量为0.15IU/(kg·d),疗程6个月;检测治疗前、治疗第八天、治疗第六个月末血清中IGF-1、IGFBP-3的浓度及身高变化;治疗第八天血清中IGF-1、IGFBP-3浓度升高30%以上者分为敏感组,低于10%以下为非敏感组,对比两组血清浓度变化并比较相应的身高速率(GV)。结论 ISS儿童用rhGH治疗第八天血清中IGF-1、IGFBP-3浓度升高30%以上,预示未来用rhGH改善其成人终身高的疗效较好。 展开更多
关键词 特发性矮小症(ISS) 类胰岛素样生长因-1(IGF-1) 类胰岛素生长因子结合蛋白-3(IGFBP-3) 重组人生长激素(rhGH) 儿童
下载PDF
维生素A、维生素E、重组人生长激素三联治疗矮小症患儿的效果 被引量:1
16
作者 李慧 《中国民康医学》 2022年第7期68-70,共3页
目的:观察维生素A、维生素E、重组人生长激素三联治疗矮小症患儿的效果。方法:选取138例矮小症患儿为研究对象,按照随机数字表法分为A、B、C三组各46例。A组给予重组人生长激素治疗,B组在A组基础上增加维生素A治疗,C组在B组基础上增加... 目的:观察维生素A、维生素E、重组人生长激素三联治疗矮小症患儿的效果。方法:选取138例矮小症患儿为研究对象,按照随机数字表法分为A、B、C三组各46例。A组给予重组人生长激素治疗,B组在A组基础上增加维生素A治疗,C组在B组基础上增加维生素E治疗。比较三组疗效、治疗前后胰岛素样生长因子(IGFs)、胰岛素生长因子结合蛋白-3(IGFBP-3)、生长发育指标(身高、体质量和骨龄)水平,以及不良反应发生率。结果:C组治疗总有效率高于B组和A组,差异均有统计学意义(P<0.05);治疗后,三组IGFs、IGFBP-3水平及身高、体质量和骨龄均高于治疗前,且C组均高于B组和A组,差异有统计学意义(P<0.05);三组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维生素A、维生素E、重组人生长激素三联治疗矮小症患儿可提高治疗总有效率及IGFs、IGFBP-3和生长发育指标水平,优于单纯重组人生长激素治疗或重组人生长激素联合维生素A治疗效果。 展开更多
关键词 维生素A 维生素E 重组人生长激素 儿童 矮小症 胰岛素样生长因子 胰岛素生长因子结合蛋白-3 不良反应
下载PDF
大剂量重组人生长激素治疗对矮小症患儿生长发育相关指标的影响 被引量:20
17
作者 袁红虹 韩雯雯 王静静 《临床误诊误治》 CAS 2021年第12期104-107,共4页
目的评价大剂量重组人生长激素(rhGH)治疗对矮小症患儿生长发育相关指标的影响。方法选择2019年1月—2020年6月收治的矮小症100例为研究对象,根据用药剂量不同分为对照组和观察组,每组50例。对照组给予小剂量rhGH治疗[0.10~0.15 U/(kg&#... 目的评价大剂量重组人生长激素(rhGH)治疗对矮小症患儿生长发育相关指标的影响。方法选择2019年1月—2020年6月收治的矮小症100例为研究对象,根据用药剂量不同分为对照组和观察组,每组50例。对照组给予小剂量rhGH治疗[0.10~0.15 U/(kg·d)],观察组给予大剂量rhGH治疗[0.16~0.20 U/(kg·d)]。比较两组治疗前后的年龄对应身高标准差积分(HtSDS_(CA))、骨龄对应身高标准差积分(HtSDS_(BA))、生长速率(GV)、预测成年身高(PAH)及血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平,并统计不良反应发生率。结果治疗后,两组HtSDS_(CA)、HtSDS_(BA)、GV、PAH及血清IGF-1和IGFBP-3水平均高于治疗前,且观察组高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论大剂量rhGH对矮小症患儿的治疗效果更明显,能更好地改善患儿的生长发育相关指标,且不增加不良反应发生率。 展开更多
关键词 矮小症 儿童 重组人生长激素 身高标准差积分 生长速率 胰岛素样生长因子-1 胰岛素样生长因子结合蛋白-3
下载PDF
维生素D结合不同剂量rhGH治疗特发性矮小症的临床研究 被引量:3
18
作者 邹兰灵 杨麒麟 王彬郦 《川北医学院学报》 CAS 2023年第8期1122-1125,共4页
目的:探讨维生素D结合不同剂量重组人生长激素(rhGH)对特发性矮小症(ISS)患儿的治疗效果及血清胰岛素样生长因子结合蛋白3(IGFBP-3)、皮质醇水平和骨龄的影响。方法:选取118例ISS患儿为研究对象,按治疗方法不同将患儿分为高剂量组(n=61... 目的:探讨维生素D结合不同剂量重组人生长激素(rhGH)对特发性矮小症(ISS)患儿的治疗效果及血清胰岛素样生长因子结合蛋白3(IGFBP-3)、皮质醇水平和骨龄的影响。方法:选取118例ISS患儿为研究对象,按治疗方法不同将患儿分为高剂量组(n=61)和低剂量组(n=57)。高剂量组给予维生素D+0.2 IU·kg^(-1)·d^(-1)rhGH治疗;低剂量组给予维生素D+0.15 IU·kg^(-1)·d^(-1)rhGH治疗,两组患儿疗程均为1年。比较两组患者治疗前后生长发育情况、血清骨代谢指标、IGFBP-3、皮质醇水平、骨龄指标及治疗期间不良反应。结果:治疗后,两组患儿身高、体重、血清骨钙素(OC)、骨碱性磷酸酶(BALP)、25羟基维生素D[25-(OH)D]、IGFBP-3水平、骨龄指数(BAI)、骨龄年龄差(BDA)均升高(P<0.05),且高剂量组高于低剂量组(P<0.05);身高标准差积分(Ht SDS)、血清皮质醇水平均降低(P<0.05),且高剂量组低于低剂量组(P<0.05)。治疗期间,两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维生素D结合高剂量rhGH对ISS患儿治疗效果更佳,且能改善血清IGFBP-3、皮质醇及骨龄水平,值得临床推广应用。 展开更多
关键词 特发性矮小症 维生素D 重组人生长激素 骨代谢 胰岛素样生长因子结合蛋白3
下载PDF
Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer 被引量:6
19
作者 Bo Jiang Xin Zhang +6 位作者 Li-Li Du Yan Wang Dong-Bo Liu Cun-Zhi Han Jie-Xian Jing Xian-Wen Zhao Xiao-Qin Xu 《World Journal of Gastroenterology》 SCIE CAS 2014年第6期1608-1613,共6页
AIM: To investigate the roles of serum insulin, insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding proteins (IGFBPs) in the initiation and progression of colorectal cancer.
关键词 Colorectal cancer INSULIN insulin-like growth factor-1 insulin-like growth factor binding protein-3 insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio
下载PDF
不同剂量重组人生长激素对小于胎龄儿矮小症患儿相关指标的影响 被引量:15
20
作者 朱一杰 《实用临床医药杂志》 CAS 2019年第19期100-102,共3页
目的探讨大剂量重组人生长激素(rhGH)与小剂量rhGH对小于胎龄儿(SGA)矮小症患儿身高标准差的增长值(△HtSDS)、生长速率(HV)、血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的影响。方法选取110例SGA矮小症患儿... 目的探讨大剂量重组人生长激素(rhGH)与小剂量rhGH对小于胎龄儿(SGA)矮小症患儿身高标准差的增长值(△HtSDS)、生长速率(HV)、血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的影响。方法选取110例SGA矮小症患儿作为研究对象,按用药剂量的不同分为2组,各55例。小剂量组患儿每日服用0.10~0.15 IU/kg的rhGH,大剂量组患儿每日服用0.16~0.20 IU/kg的rhGH,对比2组的用药效果。结果治疗后6、12、24个月,大剂量组的△HtSDS、HV、血清IGF-1、IGFBP-3水平均显著高于小剂量组(P<0.05)。结论大剂量rhGH应用于SGA矮小症患儿的治疗中优势明显,对患儿△HtSDS、HV、血清IGF-1、IGFBP-3的正性影响更大。 展开更多
关键词 重组人生长激素 剂量 小于胎龄儿 矮小症 身高标准差的增长值 生长速率 血清胰岛素样生长因子-1 胰岛素样生长因子结合蛋白-3
下载PDF
上一页 1 2 下一页 到第
使用帮助 返回顶部